A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD

BACKGROUND: The long-acting muscarinic antagonists umeclidinium (UMEC) and tiotropium (TIO) are approved once-daily maintenance therapies for COPD. This study investigated the efficacy and safety of UMEC versus TIO in COPD. METHODS: This was a 12-week, multicenter, randomized, blinded, double-dummy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Gregory, Maltais, François, Khindri, Sanjeev, Vahdati-Bolouri, Mitra, Church, Alison, Fahy, William A, Trivedi, Roopa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827908/
https://www.ncbi.nlm.nih.gov/pubmed/27103795
http://dx.doi.org/10.2147/COPD.S102494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827908/
https://www.ncbi.nlm.nih.gov/pubmed/27103795
http://dx.doi.org/10.2147/COPD.S102494

Ejemplares similares